| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Customer Service > Banks Are Ready To Outsource Their Tasks To Low Paid Destinations Like India |
|
Advice You - Banks Are Ready To Outsource Their Tasks To Low Paid Destinations Like India
Banks are ready to outsource their tasks to low paid destinations like India. As outsourcing bein According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product g concern the economist has their own way of thinking. Here's The New Economist, with a London per ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in spective that shows the outsourcing results. Outsourcing business is the business is to lower down lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. the cost in low cost destinations. Many of the cuts will be in support functions such as legal, here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe uman resources and finance. Most job cuts will be outside the US, of course - confirming the age o d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ld rule in investment banking that the further away you are from head office the more at risk is y ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc our job. While most press attention has been on the headline job cuts, the press notice also impli easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi d off shoring to India and other sites. In this, Citibank is simply catching up with the current p nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ractice of HSBC and other global banks. But its a sign of the times, nonetheless. The various eco and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ nomists give their own thinking and suggestions on the process of outsourcing. This is the way how ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi outsourcing affects the economy of a country.
Yet another sign of the vast amount of waste inhere ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a nt in big-company IT operations ... When viewed in light of similar efforts by other corporate gia dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod nts is in the midst of an IT rationalization program expected to cut a billion dollars (a billion cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin dollars!) from its IT budget - Citi's announcement will up the pressure on other large companies t tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen take a hard look at their IT spending and take advantage of new opportunities to do more with les t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel s. This will automatically generate a business flow to low cost destination like India. India has ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust high qualified and experienced professionals to handle their job in low payroll in comparison to U y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products A. In the short run, the rationalization wave could be good news for IT vendors - at least some o . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de f them - as it will involve investing in the modernization of IT plants and equipment. But in the elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip longer run, the trend at the top tier of the enterprise market is clear: IT spending is going down tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Strengthen Your Corporate Brand Image For Optimum Results Recruit & Retain The Right People By Developing A Winning Mentality
|